Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Drug ‘Chemputer’

Curator: Larry H Bernstein, MD, FCAP

Revised 9/30/2015

The ‘chemputer’ that could print out any drug

When Lee Cronin learned about the concept of 3D printers, he had a brilliant idea: why not turn such a device into a universal chemistry set that could make its own drugs?

http://www.theguardian.com/science/2012/jul/21/chemputer-that-prints-out-drugs

Professor Lee Cronin is a likably impatient presence, a one-man catalyst. “I just want to get stuff done fast,” he says. And: “I am a control freak in rehab.” Cronin, 39, is the leader of a world-class team of 45 researchers at Glasgow University, primarily making complex molecules. But that is not the extent of his ambition. A couple of years ago, at a TED conference, he described one goal as the creation of “inorganic life”, and went on to detail his efforts to generate “evolutionary algorithms” in inert matter. He still hopes to “create life” in the next year or two.

At the same time, one branch of that thinking has itself evolved into a new project: the notion of creating downloadable chemistry, with the ultimate aim of allowing people to “print” their own pharmaceuticals at home. Cronin’s latest TEDtalk asked the question: “Could we make a really cool universal chemistry set? Can we ‘app’ chemistry?” “Basically,” he tells me, in his office at the university, with half a grin, “what Apple did for music, I’d like to do for the discovery and distribution of prescription drugs.”

The idea is very much at the conception stage, but as he walks me around his labs Cronin begins to outline how that “paradigm-changing” project might progress. He has been in Scotland for 10 years and in that time he has worked hard, as any chemist worth his salt should, to get the right mix of people to produce the results he wants. Cronin’s interest has always been in complex chemicals and the origins of life. “We are pretty good at making molecules. We do a lot of self-assembly at a molecular level,” he says. “We are able to make really large molecules and I was able to get a lot of money in grants and so on for doing that.” But after a while, Cronin suggests, making complex molecules for their own sake can seem a bit limiting. He wanted to find some more life-changing applications for his team’s expertise.

A couple of years ago, Cronin was invited to an architectural seminar to discuss his work on inorganic structures. He had been looking at the way crystals grew “inorganic gardens” of tube-like structures between themselves. Among the other speakers at that conference was a man explaining the possibilities of 3D printing for conventional architectural forms. Cronin wondered if you could apply this 3D principle to structures at a molecular level. “I didn’t want to print an aeroplane, or a jaw bone,” he says. “I wanted to do chemistry.”

Advertisement

Cronin prides himself on his lateral thinking; his gift for chemistry came fairly late – he stumbled through comprehensive school in Ipswich and initially university – before realising a vocation for molecular chemistry that has seen him make a series of prize-winning, and fund-generating, advances in the field. He often puts his faith in counterintuition. “Confusions of ideas produce discovery,” he says. “People, researchers, always come to me and say they are pretty good at thinking outside the box and I usually think ‘yes, but it is a pretty small box’.” In analyzing how to apply 3D printing to chemistry, Cronin wondered in the first instance if the essentially passive idea of a highly sophisticated form of copying from a software blueprint could be made more dynamic. In his lab, they put together a rudimentary prototype of a chemical 3D printer, which could be programmed to make basic chemical reactions to produce different molecules.

First Complete Structural Study Of A Pegylated Protein

http://www.technologynetworks.com/Proteomics/news.aspx?ID=183266

Significant data obtained at NUI Galway reports first crystal structure of a protein modified with a single PEG chain.

Protein PEGylation is a technique routinely used to improve the pharmacological properties of injectable therapeutic proteins. PEG stands for polyethylene glycol, a synthetic polymer that is attached to proteins. The PEG chain artificially increases the size of the protein and improves its retention in the bloodstream. By remaining longer in the blood stream the protein therapeutic is more effective than normal.

Since PEGylation was developed in the 1970s, PEGylated proteins have significantly improved the treatment of several chronic diseases, including hepatitis C, leukemia, arthritis, and Crohn’s disease. PEGylated interferon is one of the most powerful therapeutics used to treat chronic hepatitis. Despite their importance the structure of PEGylated proteins has remained elusive. Now the first crystal structure of a protein modified with a single PEG chain has been determined through research at NUI Galway.

This important research was developed at NUI Galway by Italian PhD student Giada Cattani working with Dr. Peter Crowley, the lead author of the paper. The work also involved collaboration with Dr. Lutz Vogeley from the School of Biochemistry and Immunology at Trinity College Dublin and the crucial X-ray data was collected at the Diamond synchrotron in Oxford, UK.

Commenting on the research findings Dr. Peter Crowley from the School of Chemistry, NUI Galway commented, “The crystal structure reveals an extraordinary double helical arrangement of the protein! It is significant that this data was obtained at NUI Galway, the only Irish University to offer a degree programme in Biopharmaceutical Chemistry. This attractive programme provides training in an area that is essential for the development of new medicines and contributes to the Irish economy.”

A common approach to understand proteins is to crystallize them and determine their structure by using X-ray crystallography. This is necessary to understand what the protein looks like and how it functions. Thousands of research papers have been published about PEGylated proteins. Until the recent findings at NUI Galway there had been no success in  crystallizing a PEGylated protein. The knowledge obtained by the Crowley lab has implications for understanding how PEGylated proteins work. The NUI Galway team is also looking at ways to engineer protein assemblies based on this result.

Drugs Go Under Cover as Platelets to Destroy Cancer

• Scientists say they have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets, allowing the drugs to last longer in the body and attack both primary cancer tumors and the circulating tumor cells that can cause a cancer to metastasize. The work reportedly was tested successfully in an animal model.
• “There are two key advantages to using platelet membranes to coat anticancer drugs,” says Zhen Gu, Ph.D., corresponding author of a paper on the work and an assistant professor in the joint biomedical engineering program at North Carolina State University and the University of North Carolina at Chapel Hill. “First, the surface of cancer cells has an affinity for platelets; they stick to each other. Second, because the platelets come from the patient’s own body, the drug carriers aren’t identified as foreign objects, so last longer in the bloodstream.”
• “This combination of features means that the drugs can not only attack the main tumor site, but are more likely to find and attach themselves to tumor cells circulating in the bloodstream, essentially attacking new tumors before they start,” adds Quanyin Hu, a Ph.D. student and lead author of the paper (“Anticancer Platelet-Mimicking Nanovehicles”), which appears in Advanced Materials
• Here’s how the process works. Blood is taken from a patient (a lab mouse in the case of this research) and the platelets are collected from that blood. The isolated platelets are treated to extract the platelet membranes, which are then placed in a solution with a nanoscale gel containing the anticancer drug doxorubicin (Dox), which attacks the nucleus of a cancer cell.
• The solution is compressed, forcing the gel through the membranes and creating nanoscale spheres made up of platelet membranes with Dox-gel cores. These spheres are then treated so that their surfaces are coated with the anticancer drug TRAIL, which is most effective at attacking the cell membranes of cancer cells.
• When released into a patient’s bloodstream, these pseudo-platelets can circulate for up to 30 hours as compared to approximately six hours for the nanoscale vehicles without the coating. When one of the pseudo-platelets comes into contact with a tumor, three things happen more or less at the same time.
• First, the P-Selectin proteins on the platelet membrane bind to the CD44 proteins on the surface of the cancer cell, locking it into place. Second, the TRAIL on the pseudo-platelet’s surface attacks the cancer cell membrane. Third, the nanoscale pseudo-platelet is effectively swallowed by the larger cancer cell. The acidic environment inside the cancer cell then begins to break apart the pseudo-platelet, thus freeing the Dox to attack the cancer cell’s nucleus.
• In a study using mice, the researchers found that using Dox and TRAIL in the pseudo-platelet drug delivery system was significantly more effective against large tumors and circulating tumor cells than using Dox and TRAIL in a nano-gel delivery system without the platelet membrane.
• “We’d like to do additional pre-clinical testing on this technique,” notes Dr. Gu. “And we think it could be used to deliver other drugs, such as those targeting cardiovascular disease, in which the platelet membrane could help us target relevant sites in the body.”